Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Serious Games

Date Submitted: Feb 7, 2023
Date Accepted: Oct 24, 2023

The final, peer-reviewed published version of this preprint can be found here:

The Multidomain Metaverse Cancer Care Digital Platform: Development and Usability Study

Kim S, Jung T, Sohn DK, Chae Y, Kim YA, Kang SH, Park Y, Chang YJ

The Multidomain Metaverse Cancer Care Digital Platform: Development and Usability Study

JMIR Serious Games 2023;11:e46242

DOI: 10.2196/46242

PMID: 38032697

PMCID: 10722376

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

The Multidomain Metaverse Cancer Care Digital Platform: A Development and Usability Study

  • Sunghak Kim; 
  • Timothy Jung; 
  • Dae Kyung Sohn; 
  • Yoon Chae; 
  • Young Ae Kim; 
  • Seung Hyun Kang; 
  • Yujin Park; 
  • Yoon Jung Chang

ABSTRACT

Background:

As the cancer treatment methods have diversified and the importance of self-management, which lowers the dependence rate on direct hospital visits, has increased, effective cancer care education and management for health professionals and patients have become necessary. The metaverse is in the spotlight as a means of digital health that allows users to engage in cancer care education and management beyond physical constraints. However, it is difficult to find a multipurpose medical metaverse that can not only be utilized in the field, but also complements the current cancer care.

Objective:

This study aimed to develop an integrated metaverse cancer care platform, Dr. Meta, and examine its usability.

Methods:

We conducted a multicenter cross-sectional survey between November and December 2021. A descriptive analysis was performed to examine the users’ experiences with Dr. Meta. In addition, a supplementary open-ended question was used to ask the users about their suggestions and improvements regarding this platform.

Results:

Overall, 70 Korean participants’ (19 males and 51 females) responses were analyzed. Over half of them were satisfied with using Dr. Meta (37/70, 53.9%); they responded that it was an interesting and immersive platform (50/70, 71.5%). However, less than half of the participants perceived no discomfort in using Dr. Meta (34/70, 48.5%), and no difficulty in wearing and operating its device (30/70, 42.8%). Further, more than half of the participants reported that Dr. Meta would be helpful in non-face-to-face and non-contact services (50/70, 71.5%). In addition, more than half of them wanted to continue using this platform in the future (41/70, 58.6%), and to recommend it to others around them (42/70, 60.0%).

Conclusions:

We developed a multidomain metaverse cancer care platform that can support both health professionals and patients in non-face-to-face cancer care. The platform was uniquely disseminated and implemented for multiple regional hospitals and showed the potential to perform successful cancer care.


 Citation

Please cite as:

Kim S, Jung T, Sohn DK, Chae Y, Kim YA, Kang SH, Park Y, Chang YJ

The Multidomain Metaverse Cancer Care Digital Platform: Development and Usability Study

JMIR Serious Games 2023;11:e46242

DOI: 10.2196/46242

PMID: 38032697

PMCID: 10722376

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.